Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "In-Chang Cho"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul
Jae Heon Kim, So Young Kim, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee
Cancer Res Treat. 2019;51(1):53-64.   Published online February 20, 2018
DOI: https://doi.org/10.4143/crt.2017.468
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aims to investigate the trend in medical travel by non-Seoul residents to Seoul for treatment of prostate cancer and also to investigate the possible factors affecting the trend.
Materials and Methods
This study represents a retrospective cohort study using data from theKoreanNationalHealth Insurance System from 2002 to 2015. Annual trends were produced for proportions of patients who traveled according to the age group, economic status and types of treatment. Multiple logistic analysiswas used to determine factors affecting surgeries at medical facilities in Seoul among the non-Seoul residents.
Results
A total of 68,543 patients were defined as newly diagnosed prostate cancer cohorts from 2005 to 2014. The proportion of patients who traveled to Seoul for treatment, estimated from cases with prostate cancer-related claims, decreased slightly over 9 years (28.0 at 2005 and 27.0 at 2014, p=0.02). The average proportion of medical travelers seeking radical prostatectomy increased slightly but the increase was not statistically significant (43.1 at 2005 and 45.4 at 2014, p=0.26). Income level and performance ofrobot-assisted radical prostatectomy were significant positive factors for medical travel to medical facilities in Seoul. Combined comorbidity diseases and year undergoing surgery were significant negative factors for medical travel to medical facilities in Seoul.
Conclusion
The general trend of patients travelling from outside Seoul for prostate cancer treatment decreased from 2005 to 2014. However, a large proportion of traveling remained irrespective of direct distance from Seoul.

Citations

Citations to this article as recorded by  
  • Relationship between patient outcomes and patterns of fragmented cancer care in older adults with gastric cancer: A nationwide cohort study in South Korea
    Dong-Woo Choi, Seungju Kim, Sun Jung Kim, Dong Wook Kim, Kwang Sun Ryu, Jae Ho Kim, Yoon-Jung Chang, Kyu-Tae Han
    Journal of Geriatric Oncology.2024; 15(2): 101685.     CrossRef
  • Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study
    Seong Cheol Kim, Seungbong Han, Ji Hyung Yoon, Sungchan Park, Kyung Hyun Moon, Sang Hyeon Cheon, Gyung-Min Park, Taekmin Kwon
    Investigative and Clinical Urology.2024; 65(2): 124.     CrossRef
  • Domestic medical travel from non-Seoul regions to Seoul for initial breast cancer treatment: a nationwide cohort study
    Jae Ho Jeong, Jinhong Jung, Hee Jeong Kim, Jong Won Lee, Beom-Seok Ko, Byung Ho Son, Kyung Hae Jung, Il Yong Chung
    Annals of Surgical Treatment and Research.2023; 104(2): 71.     CrossRef
  • Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study
    Hui Ge, Liang Zhang, Xuanxuan Ma, Wen Li, Shuwen Li, Pranshu Sahgal
    European Journal of Cancer Care.2023; 2023: 1.     CrossRef
  • Cancer care patterns in South Korea: Types of hospital where patients receive care and outcomes using national health insurance claims data
    Dong‐Woo Choi, Sun Jung Kim, Seungju Kim, Dong Wook Kim, Wonjeong Jeong, Kyu‐Tae Han
    Cancer Medicine.2023; 12(13): 14707.     CrossRef
  • Regional disparities in the availability of cancer clinical trials in Korea
    Jieun Jang, Wonyoung Choi, Sung Hoon Sim, Sokbom Kang
    Epidemiology and Health.2023; 46: e2024006.     CrossRef
  • Do Patients Residing in Provincial Areas Transport and Spend More on Cancer Treatment in Korea?
    Woorim Kim, Kyu-Tae Han, Seungju Kim
    International Journal of Environmental Research and Public Health.2021; 18(17): 9247.     CrossRef
  • Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
    Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
    Cancer Research and Treatment.2020; 52(1): 301.     CrossRef
  • Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015
    Hyun Young Lee, Suyeon Park, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Jae Heon Kim
    Yonsei Medical Journal.2019; 60(3): 257.     CrossRef
  • Why is Life Expectancy in Busan Shorter than in Seoul? Age and Cause-Specific Contributions to the Difference in Life Expectancy between Two Cities
    Young-Ho Khang, Jinwook Bahk
    Yonsei Medical Journal.2019; 60(7): 687.     CrossRef
  • 10,897 View
  • 229 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis
In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee
Cancer Res Treat. 2010;42(3):157-162.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.157
AbstractAbstract PDFPubReaderePub
Purpose

The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

Materials and Methods

This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

Results

Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

Conclusion

Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Citations

Citations to this article as recorded by  
  • Association of Lymphovascular Invasion with Biochemical Recurrence and Adverse Pathological Characteristics of Prostate Cancer: A Systematic Review and Meta-analysis
    Jakub Karwacki, Marcel Stodolak, Andrzej Dłubak, Łukasz Nowak, Adam Gurwin, Kamil Kowalczyk, Paweł Kiełb, Nazar Holdun, Wojciech Szlasa, Wojciech Krajewski, Agnieszka Hałoń, Anna Karwacka, Tomasz Szydełko, Bartosz Małkiewicz
    European Urology Open Science.2024; 69: 112.     CrossRef
  • Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma
    Koustubh Amol Surana, Deepak Pandiar, Reshma Poothakulath Krishnan
    Head and Neck Pathology.2024;[Epub]     CrossRef
  • Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
    Daniel Westaby, Juan M. Jimenez-Vacas, Ana Padilha, Andreas Varkaris, Steven P. Balk, Johann S. de Bono, Adam Sharp
    Cancers.2021; 14(1): 51.     CrossRef
  • miR-205: A Potential Biomedicine for Cancer Therapy
    Neeraj Chauhan, Anupam Dhasmana, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
    Cells.2020; 9(9): 1957.     CrossRef
  • Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas
    Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, In‐Ho Cha, Sung‐Won Cho, Jin Kim
    Oral Diseases.2019; 25(4): 1158.     CrossRef
  • Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
    Philipp Wolf
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
    Norelia Torrealba, Gonzalo Rodriguez-Berriguete, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Sánchez-Chapado, Ricardo Paniagua, Mar Royuela
    The Aging Male.2018; 21(3): 211.     CrossRef
  • Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
    Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuefang Jiang, Jun Yuan
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features
    Wei Jiang, Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuan Jun, Yuefang Jiang
    Medicine.2018; 97(49): e13537.     CrossRef
  • Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración
    R.F. Velázquez-Macías, F.E. De La Torre-Rendón, G. Ramos-Rodríguez, C.A. Calzada-Mendoza, R.M. Coral-Vázquez
    Revista Mexicana de Urología.2016; 76(5): 288.     CrossRef
  • Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
    AKIRA KOMIYA, TOMONORI KATO, TAKASHI HORI, JUNYA FUKUOKA, KENJI YASUDA, HIDEKI FUSE
    International Journal of Oncology.2014; 44(1): 195.     CrossRef
  • MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer
    BERLINDA VERDOODT, MATTHIAS NEID, MARKUS VOGT, VIKTORIA KUHN, SVEN-THORSTEN LIFFERS, REIN-JÜRI PALISAAR, JOACHIM NOLDUS, ANDREA TANNAPFEL, ALIREZA MIRMOHAMMADSADEGH
    International Journal of Oncology.2013; 43(1): 307.     CrossRef
  • 9,288 View
  • 61 Download
  • 12 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP